EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Impact of Treatment With Pegvaliase on Quality of Life for Individuals With PKU

Teresa Heller, Megan Morand, Paige Roberts, S. Shahrukh Hashmi, Hope Northrup, Christina Falugi, Kate Richardson

JIMD Reports · 2026-11 · 67 (6)

DOI: 10.1002/jmd2.70111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 18.11.2026. Verfasst von Teresa Heller und 6 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management for phenylketonuria (PKU) has traditionally involved adhering to a strict low‐protein diet to maintain phenylalanine (Phe) levels within the recommended range of < 360 μmol/L. The time commitment and financial, emotional, and social burdens of adhering to a restrictive diet, as well as the neurocognitive symptoms associated with elevated Phe levels, make it challenging to manage PKU and reduce quality of life (QoL). Pegvaliase is an enzyme substitution therapy used to lower blood Phe levels and allow for relaxation of Phe‐restricted diets. Our study investigates the subjective impact of pegvaliase on QoL. We surveyed 34 individuals currently treated with pegvaliase regarding its impact on four domains of QoL: neurocognitive, emotional/psychiatric, social, and practical. There was a statistically significant improvement in every QoL domain addressed by this study after responding to pegvaliase ( p < 0.05). The majority of participants agreed or strongly agreed that pegvaliase made daily life easier and that it improved their cognitive functioning, emotional wellbeing, physical health, and social interactions. QoL aspects that remained significant challenges post‐pegvaliase included the financial burden and difficulty with insurance, feeling different or isolated from others, difficulty traveling, and strain in relationships with friends and family. The results of this study indicate that pegvaliase has an overall positive impact on QoL, including for participants with low initial Phe levels. Therefore, access to pegvaliase may be beneficial for a broader range of patients with PKU, even those with baseline Phe levels within the recommended range.

Zitieren

APA

Heller, T., Morand, M., Roberts, P., Hashmi, S. S., Northrup, H., Falugi, C., & Richardson, K. (2026). The Impact of Treatment With Pegvaliase on Quality of Life for Individuals With PKU. JIMD Reports, 67(6). https://doi.org/10.1002/jmd2.70111

Vancouver

Heller T, Morand M, Roberts P, Hashmi SS, Northrup H, Falugi C, et al. The Impact of Treatment With Pegvaliase on Quality of Life for Individuals With PKU. JIMD Reports. 2026;67(6). doi:10.1002/jmd2.70111

BibTeX
@article{Heller2026,
  author = {Heller, Teresa and Morand, Megan and Roberts, Paige and Hashmi, S. Shahrukh and Northrup, Hope and Falugi, Christina and Richardson, Kate},
  title = {The Impact of Treatment With Pegvaliase on Quality of Life for Individuals With PKU},
  journal = {JIMD Reports},
  year = {2026},
  volume = {67},
  number = {6},
  doi = {10.1002/jmd2.70111}
}
Kostenlos starten →